Key result
LMWH matches warfarin and DOACs for pulmonary embolism outcomes but carries significantly higher costs.
Why the study?
Pulmonary thromboembolism carries substantial treatment-related complications, compliance challenges, and high costs, prompting assessment of treatment costs, complications, and patient adherence across maintenance regimens over one year.
Do different maintenance anticoagulation regimens (LMWH, warfarin, DOAC) differ in efficacy, safety, and cost in patients with pulmonary thromboembolism?
Observational (n=142)
No
Do different maintenance anticoagulation regimens (LMWH, warfarin, DOAC) differ in efficacy, safety, and cost in patients with pulmonary thromboembolism?
Maintenance therapy with DOACs, warfarin, and LMWH showed similar efficacy and safety in PTE patients, but LMWH was associated with significantly higher annual costs.
Answers are grounded in this paper and cite their sources.
Higher LMWH costs without efficacy differences may guide regimen selection; leaves open randomized confirmation in PTE.
Introduction: Pulmonary thromboembolism (PTE) is a life-threatening disease, with substantial treatment-related complications, difficult follow-up, treatment compliance, and high costs. This study aimed to assess treatment costs with various maintenance therapy regimens, complications, and patient adherence to treatment over a one-year follow-up period. Materials and Methods: This observational, prospective study included 142 patients with PTE who received maintenance anticoagulation therapy between November 2020 and March 2023. The patients were observed at three-month intervals for a year. Possible treatment-related complications, recurrence, mortality, and treatment costs were recorded. Result: Our results showed that there was no significant difference in bleeding risk based on the drugs used for initial or maintenance treatment. In maintenance therapy, low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulant (DOAC) treatment regimens had similar treatment adherence and comparable efficacy and safety in terms of recurrence and bleeding (p> 0.05). Four patients (2.8%) were diagnosed with chronic thromboembolic disease. The one-year mortality rate was 24.6% (n= 35), of which 82.9% (n= 29) occurred within the first three months. Hospital mortality rates with the different maintenance therapies were 8.8% in the LMWH group, 5.7% in the warfarin group, and 3.2% in the DOAC group. The annual cost of using LMWH was higher than that of rivaroxaban, apixaban, and warfarin (p< 0.001) while there was no significant cost difference between DOACs and warfarin (p> 0.05). Conclusions: In our study, the LMWH, warfarin, and DOAC treatment regimens had similar efficacy, safety, and patient compliance. In terms of cost, LMWH was the costliest while DOAC and warfarin were similar.
No takes yet. Share an insight, caveat, or question.
ERGÜL et al. (2023) conducted an observational in Pulmonary thromboembolism (PTE) (n=142). Low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulants (DOAC) vs. Compared against each other was evaluated on Treatment costs, complications, recurrence, mortality, and treatment adherence. Maintenance therapy with LMWH, warfarin, and DOACs for pulmonary thromboembolism showed similar efficacy and safety, but LMWH incurred higher annual costs.
Synapse has enriched 10 related papers. Consider them for comparative context: